Liisa Hurme - Orion Oyj Chairman

ORINY Stock  USD 28.63  0.49  1.74%   

Chairman

Dr. Liisa Hurme was appointed Senior Vice President, Supply Chain at Orion Oyj, effective as of January 1, 2019. She has also been Chairman of the Board of Fermion Oy at the Company since January 1, 2014. She was Member of the Executive Management Board of the Company since January 1, 2008. She no longer serves as Senior Vice President, Specialty Products effective as of January 1, 2019. She has held the position since January 1, 2014. She served as Senior Vice President, Proprietary Products at the Company from January 1, 2008 until January 1, 2014. She joined the Company in 1999 as Researcher and Project Manager, Hormonal therapies, and held the position until 2001. Later on, she moved to Project Manager position and in 2002 was appointed Portfolio Manager. After two years, she became Program Leader of pharmaceutical development projects for Hormonal and Urological therapies and was appointed Head of Urology and Oncology business in 2005. Prior to Orion, she worked for Pharmacia Upjohn as Researcher at Diagnostics Unit, Sweden, and as Researcher, Development projects at ELIAS GmbH, Germany, and Institute Pasteur, France. She was Member of the Board of Directors of Finnish Bioindustries FIB and Pharmaservice Oy Member of the Economic Social Policy Committee of the European Federation of Pharmaceutical Industries and Associations EFPIA, as well as Member of the Healthcare Sector Committee of the National Emergency Supply Organization . She holds Doctorate in Philosophy degree in Biochemistry from the University of Helsinki, Faculty of Science, 1996. since 2019.
Age 56
Tenure 6 years
Professional MarksPh.D
Phone358 10 4261
Webhttps://www.orion.fi
Hurme has served as Member of the Board of Directors of Finnish Bioindustries FIB since 2010 and Pharmaservice Oy since 2014. She has also been Member of the Economic & Social Policy Committee of the European Federation of Pharmaceutical Industries and Associations EFPIA since 2010, as well as Member of the Healthcare Sector Committee of the National Emergency Supply Organization since 2014. She holds Doctorate in Philosophy degree in Biochemistry from the University of Helsinki, Faculty of Science, 1996.

Orion Oyj Management Efficiency

The company has return on total asset (ROA) of 0.2077 % which means that it generated a profit of $0.2077 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of 0.4065 %, meaning that it generated $0.4065 on every $100 dollars invested by stockholders. Orion Oyj's management efficiency ratios could be used to measure how well Orion Oyj manages its routine affairs as well as how well it operates its assets and liabilities.
Orion Oyj ADR has accumulated 100 M in total debt with debt to equity ratio (D/E) of 0.22, which may suggest the company is not taking enough advantage from borrowing. Orion Oyj ADR has a current ratio of 3.42, suggesting that it is liquid and has the ability to pay its financial obligations in time and when they become due. Debt can assist Orion Oyj until it has trouble settling it off, either with new capital or with free cash flow. So, Orion Oyj's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Orion Oyj ADR sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Orion to invest in growth at high rates of return. When we think about Orion Oyj's use of debt, we should always consider it together with cash and equity.

Similar Executives

Showing other executives

CHAIRMAN Age

Jennifer TaubertJohnson Johnson
61
Alex GorskyJohnson Johnson
64
Enrico VanniNovartis AG ADR
70
Ashley McEvoyJohnson Johnson
50
Robert JDMerck Company
58
Carlos AlbanAbbVie Inc
55
Kenneth FrazierMerck Company
67
Alex KrauerNovartis AG ADR
69
Leif JohanssonAstraZeneca PLC ADR
68
Richard GonzalezAbbVie Inc
71
Albert DVMPfizer Inc
63
Robert MichaelAbbVie Inc
55
Joaquin DuatoJohnson Johnson
62
Giovanni CaforioBristol Myers Squibb
56
Thibaut MongonJohnson Johnson
51
Joerg ReinhardtNovartis AG ADR
65
Daniel VasellaNovartis AG ADR
65
Paulus StoffelsJohnson Johnson
57
Robert BradwayAmgen Inc
62
Daniel ODayGilead Sciences
60
Orion Oyj develops, manufactures, and markets human and veterinary pharmaceuticals and active pharmaceutical ingredients in Finland, Scandinavia, other European countries, North America, and internationally. Orion Oyj was founded in 1917 and is headquartered in Espoo, Finland. Orion Oy is traded on OTC Exchange in the United States. Orion Oyj ADR [ORINY] is a Pink Sheet which is traded between brokers as part of OTC trading.

Management Performance

Orion Oyj ADR Leadership Team

Elected by the shareholders, the Orion Oyj's board of directors comprises two types of representatives: Orion Oyj inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Orion. The board's role is to monitor Orion Oyj's management team and ensure that shareholders' interests are well served. Orion Oyj's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Orion Oyj's outside directors are responsible for providing unbiased perspectives on the board's policies.
Terhi Ormio, VP Communications
Liisa Hurme, Senior Vice President Specialty Products and Chairman of the Board of Fermion Oy; Member of the Executive Management Board
MBA M, Sr Board
Juhani Kankaanpaa, Sr Board
Olli LlM, Gen Functions
Tuukka MSc, Investor Officer
Timo Lappalainen, President CEO, Chairman of the Executive Management Board
Pr MD, Sr Board
MSc MSc, Sr Board

Orion Stock Performance Indicators

The ability to make a profit is the ultimate goal of any investor. But to identify the right pink sheet is not an easy task. Is Orion Oyj a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

Additional Tools for Orion Pink Sheet Analysis

When running Orion Oyj's price analysis, check to measure Orion Oyj's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Orion Oyj is operating at the current time. Most of Orion Oyj's value examination focuses on studying past and present price action to predict the probability of Orion Oyj's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Orion Oyj's price. Additionally, you may evaluate how the addition of Orion Oyj to your portfolios can decrease your overall portfolio volatility.